Clinical trials: Depression, Unipolar
- Condition Depression, Unipolar
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Depression
Study Where Pharmaco Magnetic Resonance Imaging (MRI) Effects of AZD6765 Will be Compared to Placebo in Depressive Male and Female Subjects
The purpose of this study is to determine the effect of a single dose infusion of AZD 6765 compared with placebo and ketamine on the blood oxygen level dependent signal using fMRI (functional Magnetic Resonance Imaging) in…
- Trial name
- NCT01046630
- Testing
- AZD6765, Ketamine
- Where
- 2 sites in United Kingdom
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
A Multiple Ascending Dose Study of BCI-838 in Healthy Volunteers
This study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BCI-838 and its metabolite BCI-632 in healthy male and female subjects.
- Trial name
- NCT01548703
- Testing
- BCI-838
- Where
- Netherlands
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- BrainCells Inc.
Major Depressive Disorder
International Study to Predict Optimised Treatment - in Depression
The aim of this study is to identify genetic, physical (brain) and psychological (cognitive) markers (or combinations of them) that predict specific response to a range of antidepressants treatment (Escitalopram, Venlafaxine…
- Trial name
- iSPOT-D (NCT00693849)
- Testing
- Escitalopram, Sertraline, Venlafaxine-XR
- Where
- 20 sites in United States, Australia and 3 more
- Volunteers
- 2,688 people, healthy volunteers welcome
- Sponsor
- BRC Operations Pty. Ltd.
Major Depressive Disorder
Piloting a Novel, Mobile Cognitive Training Tool for Patients With Major Depressive Disorder (MDD)
To assess the efficacy of a mobile-device-deployed cognitive emotional treatment for depression (Moodify) versus an active control treatment (commercially available computer games).
- Trial name
- MDD (NCT02922556)
- Testing
- Computerized Plasticity-Based Adaptive Cognitive Training, Commercially available computerized training
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Posit Science Corporation
Major Depressive Disorder
An Open-label, Adaptive Design, Positron Emission Tomography Study in Healthy Male Participants to Characterize Receptor Occupancy by MIJ821 in the Brain
The purpose of this study is to confirm binding of MIJ821 to the NR2B-containing NMDA receptors in the human brain and assess the PC-RO relationship over time using positron emission tomography (PET).
- Trial name
- NCT05666687
- Testing
- MIJ821
- Where
- United Kingdom
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Major Depressive Disorder
Tolerability and Pharmacokinetics of Hypidone Hydrochloride in Healthy Subjects
This study will investigate the tolerability and pharmacokinetics of Hypidone Hydrochloride by multiple doses in 36 healthy male and female subjects who are of 18 to 55 years old.
- Trial name
- NCT04598607
- Testing
- Hypidone Hydrochloride tablets
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Zhejiang Huahai Pharmaceutical Co., Ltd.
Major Depressive Disorder
A Study of LY2216684 in Healthy Participants
This study will evaluate the pharmacodynamic and pharmacokinetic interaction of LY2216684 with alcohol in healthy participants. This study will run approximately for 34 days.
- Trial name
- NCT01380691
- Testing
- LY2216684, Alcoholic beverage
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
the Safety, Tolerability, and Pharmacokinetics Study of HEC113995
Multiple Dose Safety, Tolerability, PK and Food Effect Study of HEC113995 PA•H2O in Healthy Subjects
- Trial name
- NCT04623814
- Testing
- Food, HEC113995
- Where
- China
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Major Depressive Disorder
Evaluation of the Effects of Duloxetine on Norepinephrine
The purpose of this study is to evaluate how taking duloxetine 60mg every day affects the transfer of two normal body chemicals, 3,4-dihydroxyphenylglycol (DHPG) and norepinephrine (NE), across cells in blood and cerebrospinal…
- Trial name
- NCT00414323
- Testing
- Duloxetine, Escitalopram
- Where
- 2 sites in United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
Effect of Food, Gender, and Age on the Pharmacokinetic Profile of SUVN-911 in Healthy Subjects
The purpose of the study is to investigate the effect of Food, Gender, and Age on the Pharmacokinetic Profile of SUVN-911 in Healthy Subjects
- Trial name
- SUVN-911 (NCT03551288)
- Testing
- SUVN-911
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Suven Life Sciences Limited
Major Depressive Disorder (MDD)
Scopolamine in Healthy Volunteers
This single-site clinical trial is an open-label study to identify the safety and pharmacokinetics of DPI-386 Nasal Gel (intranasal scopolamine gel) and IV Scopolamine.
- Trial name
- NCT03874130
- Testing
- Scopolamine
- Where
- United States
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Repurposed Therapeutics, Inc.
Major Depressive Disorder, Generalized Anxiety
Scaling Mental Healthcare in COVID-19 With Voice Biomarkers
This study aims to advance research on group sessions for mental health. The first-of-its-kind study measuring various features in a group setting, combining rich metadata in creating state-of-the-art machine learning models, and…
- Trial name
- NCT04510519
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Kintsugi Mindful Wellness, Inc.
Healthy
A Multiple Ascending Oral Dose Evaluation of the Safety, Tolerability, and Pharmacokinetics of DSP-1053 and Its Metabolites in Healthy Subjects and in Subjects With Major Depressive Disorder
Double-blind, placebo-controlled, multiple ascending oral dose evaluation of the safety, tolerability, and pharmacokinetics of DSP 1053 and its metabolites in healthy subjects and in subjects with major depressive disorder
- Trial name
- MAD (NCT01774747)
- Testing
- DSP-1053
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Sumitomo Pharma America, Inc.
Major Depressive Disorder (MDD)
Food Effect Bioavailability Study of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets
An open label, randomized, two-period, two-treatment [Treatment A (Investigational product administration under fasting condition) vs Treatment B (Investigational product administration under fed condition)], two-sequence…
- Trial name
- NCT05416957
- Testing
- Vortioxetine Hemihydrobromide Orally Disintegrating Tablets
- Where
- India
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Seasons Biotechnology (Taizhou) Co., Ltd.
Major Depressive Disorder
IM and IV SPL026 Drug Product in Healthy Participants
The goal of this clinical trial is to test SPL026 given via injection into a muscle in healthy volunteers.
- Trial name
- NCT05644093
- Testing
- SPL026 IV, SPL026 IM
- Where
- United Kingdom
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Small Pharma Ltd
Depressive Disorder, Major
Study to Evaluate the Performance Validity and Test-Retest Reliability of a Computer-Administered Cognitive Test Battery in Participants With Major Depressive Disorder (MDD)
The purpose of this study is to examine concurrent validity of 8 computerized tests intended for the assessment of cognitive function in participants with Major Depressive Disorder (MDD), relative to 8 corresponding and…
- Trial name
- NCT03014544
- Testing
- Computer- administered test battery, Examiner- administered test battery
- Where
- 20 sites in United States
- Volunteers
- 585 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder
Study of Safety, Tolerability and Pharmacokinetics of NRX-1074 in Normal Healthy Volunteers
The purpose of this study is to assess the safety and tolerability of multiple oral (PO) ascending doses of NRX-1074 in normal healthy volunteers.
- Trial name
- NRX-1074 (NCT02366364)
- Testing
- NRX-1074 375 mg, NRX-1074 500 mg, NRX-1074 750 mg
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc
Mental Disorder, Schizophrenia
A Trial to Assess a Wearable Patch's Functioning to Detect Medication Ingestion
The primary purpose of the study is to evaluate the positive detection accuracy (PDA) and detection latency measures of the D-Tect patch.
- Conditions
- Mental Disorder, Schizophrenia, Major Depressive Disorder, Bipolar I Disorder
- Trial name
- NCT06372210
- Testing
- Abilify MyCite®, D-Tect Patch
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depressive Disorder
A Study of LY2216684 and Digoxin in Healthy Subjects
The purpose of this study is to determine how much digoxin gets into the blood stream and how long it takes the body to get rid of it when given with LY2216684.
- Trial name
- NCT01266590
- Testing
- LY2216684, Digoxin
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Depressive Disorder, Major, Major Depressive Disorder (MDD)
Study Of GW679769 In Major Depressive Disorder
This is a placebo-controlled, fixed dose study that will evaluate the efficacy and safety of GW679769 in subjects with major depressive disorder.
- Trial name
- NCT00102492
- Testing
- GW679769
- Where
- 31 sites in United States, Canada
- Volunteers
- 356 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline